论文信息 - Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT). - 字舞流文

Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).

H. Kluger | D. Ramies | B. Hellerstedt | N. Vogelzang | Xiao-dong Shen | P. Lara | M. Gordon | G. Edelman | C. Yasenchak